share_log

Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Huntsman Ronald Kirk

Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Huntsman Ronald Kirk

Vivos Therapeutics | 4:持股变动声明-高管 Huntsman Ronald Kirk
美股SEC公告 ·  11/27 15:49

Moomoo AI 已提取核心信息

Ronald Kirk Huntsman, CEO of Vivos Therapeutics, reported his stock holdings as of 11/26/2024. He directly holds 3,461 shares of common stock and indirectly holds 69,600 shares. The indirect holdings are noted with a footnote for further details. The total amount of shares beneficially owned by Huntsman is 73,061. This report provides insight into the CEO's stake in the company, which may interest investors monitoring executive stock ownership. The transaction status is completed, and the report does not indicate any recent buying or selling activity by Huntsman. Investors may consider this information when evaluating the company's leadership commitment and potential future performance.
Ronald Kirk Huntsman, CEO of Vivos Therapeutics, reported his stock holdings as of 11/26/2024. He directly holds 3,461 shares of common stock and indirectly holds 69,600 shares. The indirect holdings are noted with a footnote for further details. The total amount of shares beneficially owned by Huntsman is 73,061. This report provides insight into the CEO's stake in the company, which may interest investors monitoring executive stock ownership. The transaction status is completed, and the report does not indicate any recent buying or selling activity by Huntsman. Investors may consider this information when evaluating the company's leadership commitment and potential future performance.
Vivos Therapeutics首席执行官罗纳德·柯克·亨斯曼报告了截至2024年11月26日的持股情况。他直接持有3,461股普通股,间接持有69,600股。间接持股在脚注中注明,以了解更多详情。 亨斯迈实益持有的股份总额为73,061股。该报告提供了对首席执行官在该公司的股份的见解,这可能会引起监督高管股票所有权的投资者感兴趣。交易状态已完成,报告未显示亨斯迈最近的任何买入或卖出活动。 投资者在评估公司的领导承诺和潜在的未来业绩时可以考虑这些信息。
Vivos Therapeutics首席执行官罗纳德·柯克·亨斯曼报告了截至2024年11月26日的持股情况。他直接持有3,461股普通股,间接持有69,600股。间接持股在脚注中注明,以了解更多详情。 亨斯迈实益持有的股份总额为73,061股。该报告提供了对首席执行官在该公司的股份的见解,这可能会引起监督高管股票所有权的投资者感兴趣。交易状态已完成,报告未显示亨斯迈最近的任何买入或卖出活动。 投资者在评估公司的领导承诺和潜在的未来业绩时可以考虑这些信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息